Quarterly ResultMay 6, 2026, 04:14 PM
Sera Prognostics Q1 Revenue $14K; Net Loss $8.4M; Cash Runway to 2029
AI Summary
Sera Prognostics Inc. announced its first quarter 2026 financial results, reporting revenue of $14,000 and a net loss of $8.4 million. Despite the financial decline, the company successfully extended its cash runway through 2029 by redirecting investments from clinical activities to commercialization and rightsizing its operating model. Key business highlights include the publication of the landmark PRIME Randomized Trial, expansion of its European evidence base, launch of a third partnership program, and active discussions with 13 payers.
Key Highlights
- Cash runway extended through 2029 due to business review and cost structure adjustments.
- Q1 2026 revenue was $14,000, a decrease from $38,000 in Q1 2025.
- Q1 2026 net loss was $8.4 million, compared to $8.2 million in Q1 2025.
- Total operating expenses for Q1 2026 were $9.4 million, up from $9.3 million in Q1 2025.
- Published landmark PRIME Randomized Trial showing PreTRM test reduced early preterm births by 56% (<32 weeks).
- Launched third partnership program, expanding physician education and access to PreTRM to over 350 providers.
- Engaged in active discussions with 13 payers across 15 states for commercial progress.
- Company held $86.8 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2026.